NCT02601937 / 2015-002468-18: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma |
|
|
| Completed | 1 | 109 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, E7438 | Epizyme, Inc. | Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary | 10/21 | 10/21 | | |
NCT04537715: Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer |
|
|
| Completed | 1 | 42 | Europe, US | Tazemetostat, EPZ-6438, Tazverik, Itraconazole, Sporanox, Rifampin, RIF, Rifampicin, Rifadin, Rimactane | Epizyme, Inc. | All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor | 04/23 | 04/23 | | |